TABLE 3.

Systemic adverse events judged by the investigator as related to the study drug in part 2 of the studya

EventNo. of occurrences in cohort
Total placebo (n = 6)500 mg q8h (n = 6)1,000 mg q8h (n = 6)1,500 mg q12h (n = 6)
Diarrhea2
Hypoaesthesia1
Paraesthesia1
Flushing1
  • a Multiple doses of CXA-101 or placebo (6 CXA-101, 2 placebo per cohort).